ASN002 RD: Clinical Trials

1 trial of ASN002 RD, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Terminated 1
Phase 21Terminated 1

Follow ASN002 RD: new trials by email Literature Review of ASN002 RD trials Research Report on ASN002 RD

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
ASN002 Dose Escalation, ASN002 RD - Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell
Phase 1 / Phase 2TerminatedAsana BioSciences512015-05-012023-06-07

Conditions studied

Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Lymphoma, T-Cell, Peripheral (1)  ·  Neoplasms (1)  ·  Primary Myelofibrosis (1)

Sponsors

Asana BioSciences (1)

Countries

Argentina (1)  ·  United States (1)

Top investigators

Niranjan Rao, PhD (1)